Jagsonpal Pharmaceuticals completes 69.77% acquisition of Aequitas Healthcare

What Jagsonpal Pharmaceuticals announced

Jagsonpal Pharmaceuticals Ltd filed a Regulation 30 disclosure with the BSE and NSE on 7 July 2026, confirming that it has completed the purchase of a 69.77 % equity stake in Aequitas Healthcare Private Limited. The acquisition makes Aequitas a subsidiary of Jagsonpal. The filing references a prior letter dated 29 June 2026 in which the company had communicated its intention to acquire an 85 % stake in Aequitas.

"Out of the 85% stake proposed to be acquired in Aequitas, we have completed acquisition of 69.77% stake. Consequently, Aequitas has become a subsidiary of the Jagsonpal Pharmaceuticals Limited."

The announcement does not disclose any monetary consideration or financing details.

Acquisition specifics

• Target company: Aequitas Healthcare Private Limited (private company).
• Stake acquired: 69.77 % of the equity.
• Original proposal: 85 % stake, indicating that an additional 15.23 % may be acquired in the future.
• Effective date: The acquisition was reported as completed on the filing date, 7 July 2026.
• Regulatory filing: Disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30.

Key facts at a glance

Why this matters for investors

The acquisition expands Jagsonpal’s business footprint into the healthcare services segment, potentially diversifying revenue streams beyond its core pharmaceutical manufacturing operations. By converting Aequitas into a subsidiary, Jagsonpal gains consolidated control over Aequitas’ assets, contracts, and cash flows, which will be reflected in future financial statements. The pending acquisition of the remaining 15.23 % stake could further increase ownership and influence, but the current filing does not disclose any timeline or financial terms for that portion.

Conclusion

Jagsonpal Pharmaceuticals has formally recorded the purchase of a 69.77 % stake in Aequitas Healthcare, establishing it as a subsidiary. While the original plan targeted an 85 % holding, the remaining minority interest remains unacquired. No financial details were disclosed, and the company has not indicated any further regulatory approvals required beyond the current filing.